BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pirklbauer M, Sallaberger S, Staudinger P, Corazza U, Leierer J, Mayer G, Schramek H. Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells. Int J Mol Sci 2021;22:5089. [PMID: 34064989 DOI: 10.3390/ijms22105089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, Navarro-González JF, Ortiz A, Ruiz-Ortega M. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int 2023;103:282-96. [PMID: 36470394 DOI: 10.1016/j.kint.2022.10.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Salama RM, Ahmed RH, Farid AA, AbdElSattar BA, AbdelBaset RM, Youssef ME, El Wakeel SA. Gastroprotective effect of dapagliflozin in ethanol-induced gastric lesions in rats: Crosstalk between HMGB1/RAGE/PTX3 and TLR4/MyD88/VEGF/PDGF signaling pathways. Int Immunopharmacol 2023;115:109686. [PMID: 36623411 DOI: 10.1016/j.intimp.2023.109686] [Reference Citation Analysis]
3 Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, Tousoulis D. The Anti-Inflammatory Effect of Novel Antidiabetic Agents. Life 2022;12:1829. [DOI: 10.3390/life12111829] [Reference Citation Analysis]
4 González-Albarrán O, Morales C, Pérez-Maraver M, Aparicio-Sánchez JJ, Simó R. Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D. Diabetes Ther 2022;13:35-49. [PMID: 35704167 DOI: 10.1007/s13300-022-01276-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mahmoud B, Abdel-Moneim A, Negeem Z, Nabil A. The relationship between B-cell lymphoma 2, interleukin-1β, interleukin-17, and interleukin-33 and the development of diabetic nephropathy. Mol Biol Rep 2022. [PMID: 35277788 DOI: 10.1007/s11033-022-07221-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne) 2021;8:777861. [PMID: 34988095 DOI: 10.3389/fmed.2021.777861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 Müller N, Busch M, Wolf G. Antidiabetika zur Progressionshemmung der Nephropathie. Nephrologe 2022;17:34-43. [DOI: 10.1007/s11560-021-00515-0] [Reference Citation Analysis]
8 Vrachatis DA, Papathanasiou KA, Iliodromitis KE, Giotaki SG, Kossyvakis C, Raisakis K, Kaoukis A, Lambadiari V, Avramides D, Reimers B, Stefanini GG, Cleman M, Giannopoulos G, Lansky A, Deftereos SG. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs 2021;81:1381-95. [PMID: 34297330 DOI: 10.1007/s40265-021-01565-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
9 Колесников ОЛ, Колесникова АА, Тарабрина ЮО. Противовоспалительное действие ингибиторов натрий-глюкозного котранспортера 2 (обзор литературы). Естественные и Технические Науки 2021. [DOI: 10.37882/2223-2966.2021.09.15] [Reference Citation Analysis]